Business Segments · Research, development and engineering expenses
MedSurg and Neurotechnology: — Research, development and engineering expenses
Stryker MedSurg and Neurotechnology: — Research, development and engineering expenses decreased by 44.1% to $231M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 43.0%, from $405M to $231M.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 11, 2026
Rolls up toR&D
How to read this metric
Higher spending suggests a focus on future growth and innovation, whereas lower spending might indicate a focus on short-term margin expansion at the expense of the product pipeline.
Detailed definition
Includes all costs associated with the design, development, and engineering of new products and technologies within the...
Peer comparison
Standard R&D reporting for medical technology firms, often measured as a percentage of segment revenue.
Metric ID:
syk_segment_medsurg_and_neurotechnology_research_development_and_engineering_expensesHistorical Data
37 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $310M | $306M | $331M | $413M | $170.5M | $351M | $170.5M | $364M | $170.5M | $326M | $170.5M | $339M | $175.5M | $346M | $175.5M | $353M | $175.5M | $350M | $175.5M | $368M | $195M | $363M | $194M | $377M | $205M | $358M | $190M | $405M | $208M | $407M | $246M | $410M | $247M | $401M | $230M | $413M | $231M |
| QoQ Change | — | -1.3% | +8.2% | +24.8% | -58.7% | +105.9% | -51.4% | +113.5% | -53.2% | +91.2% | -47.7% | +98.8% | -48.2% | +97.2% | -49.3% | +101.1% | -50.3% | +99.4% | -49.9% | +109.7% | -47.0% | +86.2% | -46.6% | +94.3% | -45.6% | +74.6% | -46.9% | +113.2% | -48.6% | +95.7% | -39.6% | +66.7% | -39.8% | +62.3% | -42.6% | +79.6% | -44.1% |
| YoY Change | — | — | — | — | — | +13.2% | -45.0% | +19.0% | -44.3% | -1.5% | -48.5% | -17.9% | -57.5% | -1.4% | -50.0% | -3.0% | -51.8% | +7.4% | -46.2% | +8.6% | -42.5% | +4.9% | -43.9% | +6.8% | -41.9% | +2.3% | -45.7% | +10.1% | -43.5% | +12.1% | -32.2% | +8.8% | -34.5% | +12.0% | -35.8% | +2.0% | -43.0% |
Range$170.5M – $413M
CAGR-3.2%
Avg YoY Growth-19.5%
Median YoY Growth-25.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology: — research, development and engineering expenses?
- Stryker (SYK) reported medsurg and neurotechnology: — research, development and engineering expenses of $231M in Q1 2026.
- How has Stryker's medsurg and neurotechnology: — research, development and engineering expenses changed year-over-year?
- Stryker's medsurg and neurotechnology: — research, development and engineering expenses decreased by 43.0% year-over-year, from $405M to $231M.
- What does medsurg and neurotechnology: — research, development and engineering expenses mean?
- The total spending on innovation and product development for this specific segment.